VCI Wealth Management LLC Sells 5,340 Shares of Johnson & Johnson (NYSE:JNJ)

VCI Wealth Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 27.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,059 shares of the company's stock after selling 5,340 shares during the quarter. Johnson & Johnson makes up approximately 1.0% of VCI Wealth Management LLC's holdings, making the stock its 23rd largest holding. VCI Wealth Management LLC's holdings in Johnson & Johnson were worth $2,332,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson during the fourth quarter worth about $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the fourth quarter worth about $36,000. Finally, Highline Wealth Partners LLC grew its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Up 2.2%

JNJ traded up $3.54 during midday trading on Tuesday, reaching $167.90. 9,277,637 shares of the company were exchanged, compared to its average volume of 8,151,378. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The company's fifty day moving average price is $154.29 and its 200 day moving average price is $155.12. The company has a market cap of $403.99 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 2.09 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the business posted $2.82 earnings per share. The business's quarterly revenue was up 5.8% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analyst Ratings Changes

JNJ has been the topic of a number of research reports. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. UBS Group lifted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Finally, Bank of America raised their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $172.87.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.